A delightful story is unfolding in the UK, where a remarkable 6-year-old girl named Saffie Sandford is experiencing the joy of sight thanks to groundbreaking gene therapy for a rare congenital condition.
Saffie, who hails from Stevenage, was diagnosed with Leber’s Congenital Amaurosis (LCA) early in her life, a condition stemming from a mutation in the RPE 65 gene that both her parents carried unknowingly. LCA often hinders vision in low light and can make daytime visibility challenging, but the good news is that innovative treatments are now available.
When Saffie was referred to Great Ormond Street Hospital (GOSH) from Moorfields Eye Hospital, she became part of a transformative journey. GOSH had been developing an exciting new gene therapy called Luxturna, specifically designed to provide a healthy version of the RPE 65 gene. In April 2025, Saffie received her first dose, followed by a second in September.
Her mother, Lisa, joyfully shared, "Having the treatment has been life-changing; it’s like someone waved a magic wand and restored her sight in the dark. We’ve been able to take her trick or treating and to restaurants in the evening—something that was impossible before."
Saffie's improvements didn’t stop there. She now enjoys better peripheral vision in daylight, allowing her to see potential hazards and thrive in her school environment. “You wouldn’t know she had the condition just by looking at her,” Lisa remarked, reflecting the positivity that surrounds Saffie's life.
Recent studies from GOSH highlight the success of Luxturna, showing significant improvements in vision among children aged 15 months to 12 years with LCA. The research revealed that 7 out of 10 children experienced meaningful enhancements in their sight after receiving the therapy. This was measured not only through personal stories from parents but also through innovative tests that assess the electrical signals from the retina to the brain—offering a gentle way to evaluate vision in young children.
Rob Henderson, a consultant ophthalmologist at GOSH, expressed his excitement about these advancements: “For the first time, we’ve been able to show objectively that gene therapy can strengthen the visual pathways in babies and young children who are living with this rare eye condition. For many of the families we work with, even small improvements in their child’s ability to see the world around them make a profound difference.”
This inspiring journey of Saffie and countless other children represents a beacon of hope. As we share these uplifting stories of healing and progress, we celebrate the advancements in medical science that bring happiness and opportunity to families everywhere.
